A Study of ASP1951 in Subjects With Advanced Solid Tumors

Status Terminated

Clinical Trial Summary

The primary purpose of this study is to evaluate the tolerability and safety profile of ASP1951 when administered as a single agent and in combination with pembrolizumab in participants with locally advanced (unresectable) or metastatic solid tumors; characterize the pharmacokinetic profile of ASP1951 when administered as a single agent and in combination with pembrolizumab; and determine the recommended phase 2 dose (RP2D) of ASP1951 and/or maximum tolerated dose (MTD) when administered as a single agent and in combination with pembrolizumab. This study will also evaluate the anti-tumor effect of ASP1951 when administered as a single agent and in combination with pembrolizumab.

Clinical Trial Description

This is a dose-escalation and expansion study of ASP1951. The study consists of 3 periods for monotherapy and combination therapy: screening, treatment and follow up, followed by an optional Re-treatment period for participants that qualify. The monotherapy escalation cohorts will evaluate escalating dose levels of ASP1951 in participants with locally advanced (unresectable) or metastatic solid tumor malignancies including but not limited to squamous cell carcinoma of the head and neck (SCCHN), colorectal cancer, metastatic castration-resistant prostate cancer (mCRPC) and cervical cancer. The combination escalation cohorts will evaluate escalating dose levels of ASP1951 in combination with a fixed dose of pembrolizumab. For dose expansion, the tumor-specific cohorts will include participants with squamous cell carcinoma of the head and neck (SCCHN), non-small cell lung cancer (NSCLC) (all PD-L1 status), NSCLC PDL1 high, and cervical cancer, as well as participants with any tumor types that respond to study drug treatment during dose escalation. Participants may reinitiate study drug treatment in the optional Re-treatment period after confirmation that the participant meets all the re-treatment eligibility criteria. After discontinuation of study drug, all participants will complete an end-of-treatment visit, along with 30-day and 90 day safety follow-up visits from the last dose of study drug. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03799003
Study type	Interventional
Source	Astellas Pharma Inc
Contact
Status	Terminated
Phase	Phase 1
Start date	January 14, 2019
Completion date	July 6, 2023

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04972981` - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors	Phase 1
Completed	`NCT05086822` - A Study of Irinotecan Hydrochloride Liposome in Advanced Solid Tumors	Phase 1
Completed	`NCT03260322` - A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors	Phase 1
Completed	`NCT02526017` - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers	Phase 1
Recruiting	`NCT06040541` - Study of RMC-9805 in Participants With KRASG12D-Mutant Solid Tumors	Phase 1
Recruiting	`NCT05862831` - Clinical Study of PM1003 in Phase I/IIa Treatment of Advanced Malignant Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT03641794` - Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Healthy Volunteers	Phase 1
Terminated	`NCT03665129` - IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors	Phase 1
Not yet recruiting	`NCT06413680` - A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies	Phase 1/Phase 2
Recruiting	`NCT05914116` - A Study of DB-1311 in Advanced/Metastatic Solid Tumors	Phase 1/Phase 2
Completed	`NCT01693562` - A Phase 1/2 Study to Evaluate MEDI4736	Phase 1/Phase 2
Recruiting	`NCT04387916` - A Study of KC1036 in Patients With Advanced Solid Tumors	Phase 1
Completed	`NCT04095273` - Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug	Phase 1
Not yet recruiting	`NCT03692520` - Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SCT200 in Patients With Advanced Solid Tumors	Phase 1
Completed	`NCT02997176` - An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800)	Phase 1
Recruiting	`NCT04446260` - A Study of SHR-A1811 in Subjects With Advanced Malignant Solid Tumors	Phase 1
Recruiting	`NCT06239155` - A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors	Phase 1/Phase 2
Terminated	`NCT02253992` - An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma	Phase 1/Phase 2
Recruiting	`NCT06076291` - An Open-label Study of SG1827 in Subjects With Advanced Solid Tumors	Phase 1
Completed	`NCT03545971` - A Study of IBI310 for the Treatment of Patients With Advanced Solid Tumors.	Phase 1